Palisade Bio, Inc. (PALI) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Carlsbad, CA, アメリカ. 現CEOは J. D. Finley.
PALI を有する IPO日 2007-03-30, 8 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $341.72M.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
